Short- and long-term strategies for the management of hypertensive disorders of pregnancy

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 12, 2009, Pages 1581-1594

  Huda, Shahzya S ^a   Freeman, Dilys J ^a   Nelson, Scott M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Eclampsia; Fetus; Gestational hypertension; Hypertension; Preeclampsia; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM SULFATE; METHYLDOPA; NIFEDIPINE; OXPRENOLOL; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANXIETY; BED REST; BLOOD PRESSURE MEASUREMENT; BREAST FEEDING; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTINUOUS INFUSION; DEPRESSION; DIET THERAPY; DISEASE CLASSIFICATION; DIZZINESS; DOPPLER ECHOGRAPHY; DRUG CONTRAINDICATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; EXERCISE; FATIGUE; FETUS DISTRESS; HEART PALPITATION; HEMOLYTIC ANEMIA; HUMAN; HYPERHIDROSIS; HYPOTENSION; LONG TERM CARE; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MATERNAL HYPERTENSION; MATERNAL MORTALITY; MUSCLE WEAKNESS; NONHUMAN; PATHOPHYSIOLOGY; PREECLAMPSIA; PUERPERIUM; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TACHYCARDIA; VOMITING;

ANTIHYPERTENSIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 73349142378     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.147     Document Type: Review

References (141)

1. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 367(9516), 1066-1074 (2006).
2. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer- 2003-2005. In: The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. Lewis G (Ed.). CEMACH, London, UK (2007).
3. Hunter S, Robson SC. Adaptation of the maternal heart in pregnancy. Br. Heart J. 68(6), 540-543 (1992).
4. Robson SC, Boys RJ, Hunter S, Dunlop W. Maternal hemodynamics after normal delivery and delivery complicated by postpartum hemorrhage. Obstet. Gynecol. 74(2), 234-239 (1989).
5. Shennan A, Gupta M, Halligan A, Taylor DJ, de Swiet M. Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet 347(8995), 139-142 (1996).
6. Brown MA, Reiter L, Smith B, Buddle ML, Morris R, Whitworth JA. Measuring blood pressure in pregnant women: a comparison of direct and indirect methods. Am. J. Obstet. Gynecol. 171(3), 661-667 (1994).
7. Natarajan P, Shennan AH, Penny J, Halligan AW, de Swiet M, Anthony J. Comparison of auscultatory and oscillometric automated blood pressure monitors in the setting of preeclampsia. Am. J. Obstet. Gynecol. 181(5 Pt 1), 1203-1210 (1999).
8. Penny JA, Shennan AH, Halligan AW, Taylor DJ, de Swiet M, Anthony J. Blood pressure measurement in severe preeclampsia. Lancet 349(9064), 1518 (1997).
9. Peek M, Shennan A, Halligan A, Lambert PC, Taylor DJ, De Swiet M. Hypertension in pregnancy: which method of blood pressure measurement is most predictive of outcome? Obstet. Gynecol. 88(6), 1030-1033 (1996).
10. Hermida RC, Ayala DE. Prognostic value of office and ambulatory blood pressure measurements in pregnancy. Hypertension 40(3), 298-303 (2002).
11. Magee LA, Ramsay G, von Dadelszen P. What is the role of out-of-office BP measurement in hypertensive pregnancy? Hypertens. Pregnancy 27(2), 95-101 (2008).
12. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol. 158(4), 892-898 (1988).
13. Martin JN, Jr., Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet. Gynecol. 105(2), 246-254 (2005).
14. Lindenstrom E, Boysen G, Nyboe J. Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study. Am. J. Epidemiol. 142(12), 1279-1290 (1995).
15. Brown MA, Hague WM, Higgins J et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust. NZ J. Obstet. Gynaecol. 40(2), 139-155 (2000).
16. Sibai BM, Akl S, Fairlie F, Moretti M. A protocol for managing severe preeclampsia in the second trimester. Am. J. Obstet. Gynecol. 163(3), 733-738 (1990).
17. Sibai BM. Chronic hypertension in pregnancy. Obstet. Gynecol. 100(2), 369-377 (2002).
18. O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology 14(3), 368-374 (2003).
19. Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 51(4), 1002-1009 (2008).
20. Walker JJ. Pre-eclampsia. Lancet 356(9237), 1260-1265 (2000).
21. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 365(9461), 785-799 (2005).
22. Broughton Pipkin F. Risk factors for preeclampsia. N. Engl. J. Med. 344(12), 925-926 (2001).
23. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330(7491), 565 (2005).
24. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 338, b2255 (2009).
25. The Management of Severe Preeclampsia/ Eclampsia. Green Top Guidlines, (10[a]) RCOG (2006).
26. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens. Pregnancy 20(1), IX-XIV (2001).
27. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens. Pregnancy 22(2), 143-148 (2003).
28. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 51(4), 970-975 (2008).
29. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 308(5728), 1592-1594 (2005).
30. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 30(Suppl. A), S38-S42 (2009).
31. Ramsay JE, Simms RJ, Ferrell WR et al. Enhancement of endothelial function by pregnancy: inadequate response in women with Type 1 diabetes. Diabetes Care 26(2), 475-479 (2003).
32. Ramsay JE, Ferrell WR, Crawford L, Wallace AM, Greer IA, Sattar N. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J. Clin. Endocrinol. Metab. 87(9), 4231-4237 (2002).
33. Ramsay JE, Ferrell WR, Crawford L, Wallace AM, Greer IA, Sattar N. Divergent metabolic and vascular phenotypes in pre-eclampsia and intrauterine growth restriction: relevance of adiposity. J. Hypertens. 22(11), 2177-2183 (2004).
34. Ramsay JE, Stewart F, Greer IA, Sattar N. Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG 110(11), 1029-1031 (2003).
35. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111(5), 649-658 (2003).
36. Makris A, Thornton C, Thompson J et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 71(10), 977-984 (2007).
37. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50(6), 1142-1147 (2007).
38. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350(7), 672-683 (2004).
39. Thadhani R, Ecker JL, Mutter WP et al. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension 43(5), 988-992 (2004).
40. Rajakumar A, Doty K, Daftary A, Harger G, Conrad KP. Impaired oxygen-dependent reduction of HIF-1a and -2 a proteins in pre-eclamptic placentae. Placenta 24(2-3), 199-208 (2003).
41. Venkatesha S, Toporsian M, Lam C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12(6), 642-649 (2006).
42. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355(10), 992-1005 (2006).
43. Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am. J. Epidemiol. 155(3), 203-209 (2002).
44. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG 113(5), 580-589 (2006).
45. Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension 52(5), 873-880 (2008).
46. D'Anna R, Baviera G, Corrado F et al. Adiponectin and insulin resistance in early- and late-onset pre-eclampsia. BJOG 113(11), 1264-1269 (2006).
47. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46(5), 1077-1085 (2005).
48. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet. Gynecol. 104(6), 1367-1391 (2004).
49. Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting preeclampsia. Mol. Aspects Med. 28(2), 227-244 (2007).
50. Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First trimester maternal serum placental protein 13 for the prediction of preeclampsia in women with a priori high risk. Prenat. Diagn. 29(8), 781-789 (2009).
51. Son G, Lim C, Hur HW et al. OP11.03: Prediction of preeclampsia by second trimester serum screening and uterine artery Doppler velocimetry. Ultrasound Obstet. Gynecol. 34(Suppl. 1), 96 (2009).
52. Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet. Gynecol. 111(6), 1403-1409 (2008).
53. Meler E, Mula R, Masoller N, Figueras F, Gratacos E. OC20.02: First-trimester maternal haemodynamic evaluation in women with abnormal uterine Doppler for the prediction of preeclampsia. Ultrasound Obstet. Gynecol. 34(Suppl. 1), 36-37 (2009).
54. Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 107(2), 196-208 (2000).
55. Yu CK, Papageorghiou AT, Boli A, Cacho AM, Nicolaides KH. Screening for pre-eclampsia and fetal growth restriction in twin pregnancies at 23 weeks of gestation by transvaginal uterine artery Doppler. Ultrasound Obstet. Gynecol. 20(6), 535-540 (2002).
56. Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Ultrasound Obstet. Gynecol. 22(3), 233-239 (2003).
57. Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free b-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet. Gynecol. 27(6), 658-663 (2006).
58. Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free b-hCG and with second-trimester uterine artery Doppler. Prenat. Diagn. 25(10), 949-953 (2005).
59. Vainio M, Kujansuu E, Koivisto AM, Maenpaa J. Bilateral notching of uterine arteries at 12-14 weeks of gestation for prediction of hypertensive disorders of pregnancy. Acta Obstet. Gynecol. Scand. 84(11), 1062-1067 (2005).
60. Nicolaides KH, Bindra R, Turan OM et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet. Gynecol. 27(1), 13-17 (2006).
61. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am. J. Obstet. Gynecol. 193(2), 429-436 (2005).
62. Papageorghiou AT, Yu CK, Erasmus IE, Cuckle HS, Nicolaides KH. Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery Doppler. BJOG 112(6), 703-709 (2005).
63. Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med. J. 46(5), 826-831 (2005).
64. Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 109(2), 161-167 (2002).
65. Chiaffarino F, Parazzini F, Paladini D et al. A small randomised trial of low-dose aspirin in women at high risk of preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 112(2), 142-144 (2004).
66. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49(4), 818-824 (2007).
67. Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am. J. Obstet. Gynecol. 198(2), 175 e171-e176 (2008).
68. Meher S, Abalos E, Carroli G. Bed rest with or without hospitalisation for hypertension during pregnancy. Cochrane Database Syst. Rev. (4), CD003514 (2005).
69. Meher S, Duley L. Exercise or other physical activity for preventing preeclampsia and its complications. Cochrane Database Syst. Rev. (2), CD005942 (2006).
70. Meher S, Duley L. Rest during pregnancy for preventing pre-eclampsia and its complications in women with normal blood pressure. Cochrane Database Syst. Rev. (2), CD005939 (2006).
71. Duley L, Henderson-Smart D, Meher S. Altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst. Rev. (4), CD005548 (2005).
72. Kramer MS, Kakuma R. Energy and protein intake in pregnancy. Cochrane Database Syst. Rev. (4), CD000032 (2003).
73. Meher S, Duley L. Garlic for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. (3), CD006065 (2006).
74. Makrides M, Crowther CA. Magnesium supplementation in pregnancy. Cochrane Database Syst. Rev. (4), CD000937 (2001).
75. Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst. Rev. 3, CD003402 (2006).
76. Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst. Rev. 3, CD001059 (2006).
77. Chappell LC, Seed PT, Briley AL et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 354(9181), 810-816 (1999).
78. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebocontrolled trial. Lancet 367(9517), 1145-1154 (2006).
79. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS. Vitamins C and E and the risks of preeclampsia and perinatal complications. N. Engl. J. Med. 354(17), 1796-1806 (2006).
80. Villar J, Purwar M, Merialdi M et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG 116(6), 780-788 (2009).
81. Spinnato JA, 2nd, Freire S, Pinto ESJL et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet. Gynecol. 110(6), 1311-1318 (2007).
82. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. (2), CD004659 (2007).
83. Bonnar J, McNicol GP, Douglas AS. Coagulation and fibrinolytic systems in pre-eclampsia and eclampsia. Br. Med. J. 2(5752), 12-16 (1971).
84. Urban G, Vergani P, Tironi R et al. Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy. Int. J. Fertil. Womens Med. 52(2-3), 59-67 (2007).
85. Rey E, Garneau P, David M et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J. Thromb. Haemost. 7(1), 58-64 (2009).
86. Churchill D, Beevers GD, Meher S, Rhodes C. Diuretics for preventing pre-eclampsia. Cochrane Database Syst. Rev. (1), CD004451 (2007).
87. Meher S, Duley L. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. (2), CD006490 (2007).
88. Meher S, Duley L. Progesterone for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. (4), CD006175 (2006).
89. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. (1), CD002252 (2007).
90. von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J. Obstet. Gynaecol. Can. 24(12), 941-945 (2002).
91. Magee LA. The CHIPS trial: Control of Hypertension In Pregnancy Study. Current Controlled Trials (2009).
92. Magee LA, von Dadelszen P, Chan S et al. The Control of Hypertension In Pregnancy Study pilot trial. BJOG 114(6), 770, e713-e720 (2007).
93. Houlihan DD, Dennedy MC, Ravikumar N, Morrison JJ. Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance. J. Perinat. Med. 32(4), 315-319 (2004).
94. Redman CW, Beilin LJ, Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Br. J. Obstet. Gynaecol. 84(6), 419-426 (1977).
95. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1(8273), 647-649 (1982).
96. Rubin PC, Butters L, Clark DM et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet 1(8322), 431-434 (1983).
97. Gallery ED, Ross MR, Gyory AZ. Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. Br. Med. J. (Clin. Res. Ed.) 291(6495), 563-566 (1985).
98. Pickles CJ, Symonds EM, Broughton Pipkin F. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancyinduced hypertension. Br. J. Obstet. Gynaecol. 96(1), 38-43 (1989).
99. Waterman EJ, Magee LA, Lim KI, Skoll A, Rurak D, von Dadelszen P. Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review. Hypertens. Pregnancy 23(2), 155-169 (2004).
100. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 301(6752), 587-589 (1990).
101. Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet. Gynecol. 70(3 Pt 1), 323-327 (1987).
102. Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am. J. Obstet. Gynecol. 162(4), 960-966; discussion 966-967 (1990).
103. Mabie WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet. Gynecol. 70(3 Pt 1), 328-333 (1987).
104. Reynolds B, Butters L, Evans J, Adams T, Rubin PC. First year of life after the use of atenolol in pregnancy associated hypertension. Arch. Dis. Child 59(11), 1061-1063 (1984).
105. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 327(7421), 955-960 (2003).
106. Constantine G, Beevers DG, Reynolds AL, Luesley DM. Nifedipine as a second line antihypertensive drug in pregnancy. Br. J. Obstet. Gynaecol. 94(12), 1136-1142 (1987).
107. Broughton Pipkin F, Lawrence MR. The effect of nitrendipine (NIT) on maternal and fetal blood pressure, uterine blood flow, and blood gas status in pregnant sheep. J. Cardiovasc. Pharmacol. 12(Suppl. 6), S123-S125 (1988).
108. Serra-Serra V, Kyle PM, Chandran R, Redman CW. The effect of nifedipine and methyldopa on maternal cerebral circulation. Br. J. Obstet. Gynaecol. 104(5), 532-537 (1997).
109. Gallery ED, Hunyor SN, Gyory AZ. Plasma volume contraction: a significant factor in both pregnancy-associated hypertension (pre-eclampsia) and chronic hypertension in pregnancy. QJ Med. 48(192), 593-602 (1979).
110. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am. J. Obstet. Gynecol. 150(7), 831-835 (1984).
111. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med. 354(23), 2443-2451 (2006).
112. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensinconverting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am. J. Med. 96(5), 451-456 (1994).
113. Lip GY, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensin-convertingenzyme inhibitors in early pregnancy. Lancet 350(9089), 1446-1447 (1997).
114. Chung NA, Lip GY, Beevers M, Beevers DG. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357(9268), 1620-1621 (2001).
115. Gerald G. Briggs RKF, Sumner J. Yaffe. Drugs in Pregnancy and Lactation : a Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins, London, UK (2005).
116. Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart 77(2), 154-158 (1997).
117. Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet. Gynecol. Scand. 74(10), 772-776 (1995).
118. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 357(9273), 2002-2006 (2001).
119. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 366(9499), 1797-1803 (2005).
120. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335(7627), 974 (2007).
121. Green A, Beral V, Moser K. Mortality in women in relation to their childbearing history. BMJ 297(6645), 391-395 (1988).
122. Ness RB, Harris T, Cobb J et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N. Engl. J. Med. 328(21), 1528-1533 (1993).
123. Lawlor DA, Emberson JR, Ebrahim S et al. Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing? Findings from the British Women's Heart and Health Study and the British Regional Heart Study. Circulation 107(9), 1260-1264 (2003).
124. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 325(7356), 157-160 (2002).
125. Allender S PV, Scarborough P, Kaur A, Rayner M. Coronary Heart Disease Statistics. British Heart Foundation, London, UK (2008).
126. Levin RI. The puzzle of aspirin and sex. N. Engl. J. Med. 352(13), 1366-1368 (2005).
127. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N. Engl. J. Med. 300(24), 1350-1358 (1979).
128. Legato MJ. Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy. Am. J. Cardiol. 86(12A), 15L-18L (2000).
129. Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 322(7290), 832 (2001).
130. Lawlor DA, Whincup P, Emberson JR, Rees K, Walker M, Ebrahim S. The challenge of secondary prevention for coronary heart disease in older patients: findings from the British Women's Heart and Health Study and the British Regional Heart Study. Fam. Pract. 21(5), 582-586 (2004).
131. Iinuma H. [Follow-up study on women suffered from severe toxemia of pregnancy]. Nippon Sanka Fujinka Gakkai Zasshi 40(8), 980-990 (1988).
132. Freeman DJ, McManus F, Brown EA et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 44(5), 708-714 (2004).
133. Sattar N, Ramsay J, Crawford L, Cheyne H, Greer IA. Classic and novel risk factor parameters in women with a history of preeclampsia. Hypertension 42(1), 39-42 (2003).
134. Hubel CA, Powers RW, Snaedal S et al. C-reactive protein is elevated 30 years after eclamptic pregnancy. Hypertension 51(6), 1499-1505 (2008).
135. Lampinen KH, Ronnback M, Kaaja RJ, Groop PH. Impaired vascular dilatation in women with a history of pre-eclampsia. J. Hypertens. 24(4), 751-756 (2006).
136. Hooper L, Summerbell CD, Higgins JP et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ 322(7289), 757-763 (2001).
137. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/ CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286(1), 64-70 (2001).
138. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
139. Buhimschi IA, Zhao G, Funai EF et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am. J. Obstet. Gynecol. 199(5), 551 e551-e516 (2008).
140. Blumenstein M, McMaster MT, Black MA et al. A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics 9(11), 2929-2945 (2009).
141. Pasupathy D, Dacey A, Cook E, Charnock-Jones DS, White IR, Smith GC. Study protocol. A prospective cohort study of unselected primiparous women: the pregnancy outcome prediction study. BMC Pregnancy Childbirth 8, 51 (2008).